Tresiba Monitoring Schedule: Labs & Exams You Need on Insulin Degludec

What Is Tresiba and How Does It Work?

Insulin degludec is an ultra-long-acting basal insulin analog that forms soluble multi-hexamer chains under the skin after injection. These chains slowly release individual insulin molecules into circulation, producing a flat, stable action profile with a duration exceeding 42 hours and a half-life of roughly 25 hours. That profile is meaningfully different from insulin glargine U-300 or detemir and matters when you are thinking about monitoring, because Tresiba reaches steady-state only after 3 to 4 days of consistent dosing.

The Pharmacokinetics That Shape Your Monitoring

After subcutaneous injection, degludec self-associates into soluble di-hexamers that further aggregate into long multi-hexamers. Zinc and phenol act as depot stabilizers. Pharmacokinetic studies in healthy subjects show that the coefficient of variation for day-to-day glucose-lowering effect is roughly 20% with degludec compared with approximately 82% with NPH insulin. Lower variability means fewer surprise hypoglycemic readings, which changes how aggressively you titrate the dose and how frequently you need to check fasting glucose once stable.

Sex-Specific Pharmacology

Women with type 1 diabetes tend to have lower total daily insulin requirements per kilogram of lean body mass compared with men, a difference tied to estrogen's effect on adiponectin and insulin sensitivity. A post-hoc analysis of the BEGIN trials showed that women on degludec achieved similar HbA1c reductions to men but experienced numerically fewer confirmed hypoglycemic episodes, though the study was not powered to confirm this sex difference definitively. This evidence gap matters: dosing tables derived mostly from mixed-sex or male-predominant populations may overestimate the basal insulin dose a woman needs.

The Core Monitoring Schedule at a Glance

The monitoring schedule below applies to most adult women using Tresiba as basal insulin. Individual clinician judgment, your specific type of diabetes, comorbidities, and life stage will modify it.

Glycemic Monitoring

HbA1c. The American Diabetes Association 2024 Standards of Care recommend HbA1c testing every 3 months when glycemia is not at goal or when therapy has changed, and every 6 months once stable. For most non-pregnant women with diabetes, the target is below 7.0%. Women with PCOS who have insulin resistance and concurrent hyperandrogenism may need more aggressive early titration with correspondingly more frequent HbA1c checks at initiation.

Fasting plasma glucose (FPG). Because degludec's primary role is basal glucose control overnight, fasting glucose is the most direct window into whether the dose is right. The standard titration algorithm from the DEVOTE trial protocol used a twice-weekly fasting self-monitored blood glucose (SMBG) target of 71 to 90 mg/dL (3.9 to 5.0 mmol/L) to guide dose adjustment. During titration, check fasting glucose every morning. Once stable, daily fasting glucose remains the sentinel number.

Continuous glucose monitoring (CGM). CGM adds time-in-range (TIR) data that HbA1c misses, particularly the amplitude and timing of nocturnal dips. The DEVOTE study documented a 34% lower rate of nocturnal confirmed hypoglycemia with degludec versus glargine U-100 (1.41 vs. 2.14 episodes per patient-year, rate ratio 0.65, 95% CI 0.58 to 0.73). If you are using CGM, review your overnight glucose trace specifically from 00:00 to 06:00. Flat overnight curves at 70 to 140 mg/dL suggest the dose is right.

Kidney and Metabolic Labs

| Test | Frequency | Notes for women | |---|---|---| | Serum creatinine / eGFR | Annually (more often if eGFR <60) | Pregnancy reduces serum creatinine norms; use pregnancy-specific reference ranges | | Urine albumin-to-creatinine ratio (UACR) | Annually | Elevated in PCOS even before overt nephropathy | | Comprehensive metabolic panel | Annually | Includes electrolytes, LFTs | | Fasting lipid panel | Annually | Women with PCOS have high rates of dyslipidemia | | TSH | At baseline and if symptoms suggest thyroid dysfunction | Postpartum thyroiditis affects 5-10% of women with type 1 diabetes |

Degludec itself is cleared through proteolytic degradation rather than renal excretion, so dose adjustment for reduced kidney function is not required by pharmacokinetic necessity alone. However, FDA prescribing information for Tresiba recommends intensified glucose monitoring in patients with renal impairment because hypoglycemia risk rises as GFR falls.

Eye and Foot Exams

Annual dilated fundus examination is standard for all people with diabetes. Women with rapid glycemic improvement (such as when starting basal insulin after a period of poor control) carry a short-term risk of worsening diabetic retinopathy, a phenomenon documented in the DCCT study. If your HbA1c drops more than 2 percentage points in 3 months after starting Tresiba, schedule an eye exam within 3 months rather than waiting a year.

Annual comprehensive foot exam with monofilament testing, pulses, and inspection applies to type 2 diabetes in particular. Women with long-standing type 1 diabetes who have achieved good glycemic control on degludec should continue annual exams even if they have never had a foot complication.

Monitoring Through Each Life Stage

Reproductive Years and the Menstrual Cycle

Insulin sensitivity in women is not constant across the month. Progesterone in the luteal phase (days 15 to 28) increases insulin resistance, which can raise fasting glucose by 10 to 30 mg/dL compared with the follicular phase. Many women notice this pattern before they have named it. Keep a cycle-phase log alongside your glucose log for at least 2 to 3 months after starting Tresiba. This lets you and your clinician determine whether a modest dose increase of 1 to 2 units in the luteal phase makes sense for you specifically. There is no randomized trial comparing fixed-dose versus cycle-adjusted basal insulin in women with type 1 diabetes, and that evidence gap deserves acknowledgment.

PCOS

Women with PCOS who develop type 2 diabetes often have significant underlying insulin resistance driven by hyperandrogenism and chronic low-grade inflammation. Metformin is typically the first-line oral agent and may continue alongside Tresiba. In this group, fasting glucose should be monitored daily during the first 3 months on degludec, and HbA1c checked at 3 months regardless of how stable you feel, because the basal-only approach may be insufficient if post-meal glucose excursions are large. A 2020 review in Fertility and Sterility noted that hyperandrogenism in PCOS independently predicts higher glucose variability, meaning HbA1c alone may underestimate true glycemic burden in this population.

Trying to Conceive

If you are trying to conceive while on insulin degludec, your HbA1c target tightens to below 6.5% before conception, with a goal closer to 6.0% if achievable without severe hypoglycemia. The ACOG Practice Bulletin on Pregestational Diabetes Mellitus (PB 201) recommends pre-conception glycemic optimization and folic acid supplementation at 400 mcg daily (or 4 mg daily with prior neural tube defect). Begin monitoring HbA1c every 3 months and daily fasting glucose without exception.

Pregnancy

This is covered in detail in the dedicated pregnancy section below.

Perimenopause

Estrogen decline in perimenopause alters insulin sensitivity in unpredictable ways. Some women become more insulin resistant as estrogen falls; others experience hypoglycemic episodes they did not have in their reproductive years. Because degludec's ultra-long action reduces day-to-day variability, it may buffer some hormonal swings better than shorter-acting basal insulins, though no head-to-head perimenopausal trial has tested this directly. If you are perimenopausal, monitor fasting glucose daily and flag any new pattern of nocturnal hypoglycemia to your clinician, because this may be the first sign that your basal dose needs downward adjustment as estrogen continues to fall.

Hot flashes disturb sleep and nocturnal glucose readings. If your CGM shows glucose spikes at 2 to 4 a.m. That correlate with waking episodes, discuss whether vasomotor symptom management (including hormone therapy, where appropriate) might indirectly stabilize your overnight glycemia.

Post-Menopause

Post-menopausal women with type 2 diabetes on insulin degludec should have annual UACR and eGFR checks, because cardiovascular and renal risk both accelerate after menopause. The DEVOTE trial population included a large proportion of older adults with established cardiovascular disease; the non-inferiority to glargine on MACE applies here and provides some reassurance about degludec's cardiovascular safety profile in older women.

Pregnancy, Lactation, and Contraception

Pregnancy category and human data. Insulin degludec does not have a formal FDA pregnancy letter category under the current labeling system. The FDA label for Tresiba states that available human data are insufficient to establish a drug-associated risk of major birth defects or miscarriage. Animal studies used doses 5 to 10 times the human dose and showed no teratogenicity or embryo-fetal toxicity. The label advises use in pregnancy only if the potential benefit justifies the potential risk.

What this means in practice. Most clinical guidance, including ACOG Practice Bulletin 201, recommends NPH insulin (human insulin isophane) as the preferred basal insulin in pregnancy because it has the largest body of safety data. Insulin glargine U-100 has accumulated substantial observational data as well. Degludec's ultra-long half-life (approximately 25 hours) has raised theoretical concerns about dose adjustment flexibility during pregnancy, a period when insulin requirements change rapidly, particularly in the third trimester when requirements may increase 50 to 100% above pre-pregnancy levels. No large prospective trial has studied degludec in pregnancy, and this evidence gap should inform shared decision-making.

If you become pregnant while on degludec. Do not stop insulin abruptly. Contact your care team immediately. A switch to NPH or glargine U-100 under close supervision may be considered. HbA1c should be checked every 4 weeks in pregnancy rather than every 3 months, and fasting plasma glucose should be checked at least twice daily. Pre-meal and 1-hour post-meal targets in pregnancy are: fasting below 95 mg/dL, 1-hour post-meal below 140 mg/dL, and 2-hour post-meal below 120 mg/dL per ADA 2024 guidance.

Lactation. Endogenous insulin does not pass into breast milk in significant amounts, and analog insulins including degludec are large molecules unlikely to be absorbed intact through the neonatal gut. The FDA label states there are no data on degludec in human milk, effects on the breastfed infant, or effects on milk production. Breastfeeding reduces maternal glucose, so women on insulin who are breastfeeding should expect lower insulin requirements and heightened hypoglycemia risk, particularly in the first 6 weeks postpartum. Check fasting glucose before each breastfeeding session if you are on a fixed-dose basal regimen.

Contraception. Insulin degludec is not a teratogen in animal models, but given the lack of human pregnancy data, women of reproductive potential who want to avoid pregnancy should use effective contraception while on degludec and discuss the switch to an insulin with better pregnancy data when planning conception.

Who This Monitoring Schedule Is Right For, and Who Needs More

Standard Monitoring Fits You If:

• You have stable, well-controlled type 1 or type 2 diabetes with HbA1c at or near goal.
• You have been on degludec for at least 3 to 4 days (one steady-state cycle) and your fasting glucose readings are consistent.
• You have no significant renal or hepatic impairment.
• You are not pregnant, not actively trying to conceive, and not breastfeeding.

You Need More Frequent Monitoring If:

• You are newly starting degludec or have just had a dose change. Check fasting glucose daily and review your titration with your clinician every 1 to 2 weeks.
• You have eGFR below 60 mL/min/1.73 m2. Hypoglycemia risk rises as kidney function declines, and you should check glucose at least twice daily.
• You are perimenopausal with irregular cycles and fluctuating insulin requirements. Daily fasting glucose plus a midday check helps you catch both hypo- and hyperglycemic trends.
• You are pregnant or postpartum. This requires a full team including an endocrinologist or maternal-fetal medicine specialist.
• You have PCOS with significant insulin resistance and erratic fasting readings. HbA1c every 3 months without exception, plus daily fasting glucose.

The table below is a WomanRx-developed framework for life-stage-specific monitoring intensity on insulin degludec. No published guideline has aggregated this by female life stage in a single reference.

| Life Stage | HbA1c Frequency | Fasting Glucose | Additional Monitoring | |---|---|---|---| | Reproductive years (stable) | Every 6 months | Daily | Cycle-phase glucose log | | Luteal phase titration period | Every 3 months | Twice daily | Progesterone-phase dose review | | PCOS, newly diagnosed T2D | Every 3 months | Daily | UACR, lipids annually | | Trying to conceive | Every 3 months | Daily + pre-meal | Pre-conception HbA1c <6.5% | | Pregnancy | Every 4 weeks | Twice daily minimum | 1-hr post-meal targets | | Postpartum / breastfeeding | Every 3 months | Before each feed | Hypoglycemia risk counseling | | Perimenopause | Every 3 months | Daily | Overnight CGM trace | | Post-menopause (stable) | Every 6 months | Daily | Annual UACR, eGFR, lipids |

The DEVOTE Trial: What It Tells You About Safety Monitoring

The DEVOTE trial enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk and compared insulin degludec with insulin glargine U-100 over a median of 2 years. The primary endpoint was a composite of nonfatal MI, nonfatal stroke, and cardiovascular death. Degludec was non-inferior to glargine (rate ratio 0.91, 95% CI 0.78 to 1.06).

The secondary endpoint that matters most for monitoring was nocturnal hypoglycemia. Degludec produced 34% fewer confirmed nocturnal hypoglycemic episodes, defined as blood glucose below 56 mg/dL between midnight and 6 a.m. (rate ratio 0.65, 95% CI 0.58 to 0.73). This finding has a direct implication for your monitoring schedule: if you switch from glargine to degludec and your overnight CGM or fasting SMBG suddenly improves, that is an expected finding, not a signal to immediately reduce the dose. Give the drug 3 to 4 days to reach steady state and review a 7-day fasting glucose average before adjusting.

The trial enrolled approximately 35% women, and no sex-stratified analysis of nocturnal hypoglycemia rates was published in the primary paper. That is the evidence gap: we extrapolate the 34% reduction to women from a mixed-sex trial.

As noted by the DEVOTE steering committee in their primary publication in the New England Journal of Medicine: "Insulin degludec was non-inferior to insulin glargine with respect to the rate of major adverse cardiovascular events and superior with respect to the rate of severe hypoglycemia."

Drug Interactions and Labs That Signal Trouble

Several drug classes alter your monitoring needs on degludec.

GLP-1 receptor agonists. Many women with type 2 diabetes or PCOS are prescribed a GLP-1 agonist (semaglutide, liraglutide, dulaglutide) alongside basal insulin. The combination effectively reduces HbA1c but increases hypoglycemia risk at initiation. When adding a GLP-1 agonist to existing degludec, check fasting glucose daily for the first 4 weeks and expect your clinician to reduce the basal insulin dose by 20% preemptively per ADA 2024 Standards of Care.

Corticosteroids. Women with autoimmune conditions, including thyroid disease and lupus (both more common in women), who receive corticosteroid courses will see fasting and post-meal glucose rise significantly. Degludec's dose may need to increase by 20 to 50% during steroid courses. Check fasting and bedtime glucose daily during any steroid taper.

Beta-blockers. These can mask tachycardia as a hypoglycemia warning sign. Women on beta-blockers for hypertension or migraine prevention should rely on sweating and hunger as hypoglycemia cues and check glucose more frequently.

Thyroid hormone changes. Hypothyroidism increases insulin sensitivity and can cause hypoglycemia on a fixed basal dose; hyperthyroidism does the opposite. Because postpartum thyroiditis affects roughly 5 to 10% of women with type 1 diabetes, TSH monitoring at 3 and 6 months postpartum is warranted alongside your glucose monitoring if you have type 1 disease.

Titrating the Dose: The "2-0-2" Rule and When to Stop Adjusting

The most widely studied titration algorithm for once-daily basal insulin uses a step-wise fasting glucose target. The algorithm used in the DEVOTE and BEGIN trials adjusts the dose in increments of 2 units every 3 days if fasting glucose exceeds 90 mg/dL, holds the dose if fasting glucose is between 71 and 90 mg/dL, and reduces the dose by 2 units if fasting glucose falls below 71 mg/dL on two consecutive mornings.

Because degludec takes 3 to 4 days to reach a new steady state after each adjustment, you should wait at least 3 days between dose changes. This is different from NPH or glargine U-100, which reach steady state in 2 days. Impatient titration (adjusting every 1 to 2 days) is a common monitoring error that leads to dose stacking and nocturnal hypoglycemia.

Stop upward titration and contact your clinician if:

• Any fasting glucose reading falls below 70 mg/dL.
• You have a confirmed nocturnal hypoglycemic episode (glucose below 54 mg/dL at any point between midnight and 6 a.m.).
• Your fasting glucose has been below 90 mg/dL on 3 consecutive mornings even without a recent dose increase, because this may indicate that degludec is reaching peak steady state effect.